



## PSMA in Prostate Cancer

Guest Editor:

**Dr. Finn Edler von Eyben**

Center of Tobacco Control  
Research, Odense, Denmark

finn113edler@mail.tele.dk

Deadline for manuscript  
submissions:

**30 April 2021**

### Message from the Guest Editor

Prostate Cancer has the second highest mortality for men in Western Societies. Prostate Specific Membrane Antigen (PSMA) is a glycoprotein that is highly expressed in plasma membrane of prostate cancer especially in the most aggressive forms for prostate cancer. In the recent decade PSMA PET/CT has become widely used in diagnostics of patients with metastatic castration-resistant prostate cancer (mCRPC). PSMA PET/CT has a high detection rate even for patients with low values of prostate specific antigen (PSA). Staging with PSMA PET/CT change planned treatment for more than a quarter of the patients. Radioligands can bind to the extracellular part of PSMA. Thereby the radioligand is absorbed into the cancer cells and damage the DNA of the cells. PSMA radioligand therapy is a safe and effective treatment of patients with mCRPC as documented in preliminary results of a randomized trial, TheraP. This issue up-to-date information on the use of PSMA for diagnostics and treatment of patients with prostate cancer. The issue serves as a very useful resource tool for patients, physicians, and researchers dealing with the challenge of mCRPC.





## Editors-in-Chief

**Prof. Dr. Charles Brennan**

**Prof. Dr. Andreas Taubert**

**Prof. Dr. Kurt A. Jellinger**

**Prof. Dr. Ian A. Nicholls**

**Prof. Dr. Stephen A. Bustin**

**Prof. Dr. Xiaofeng Jia**

**Prof. Dr. Maurizio Battino**

**Prof. Dr. Guido R.M.M. Haenen**

**Prof. Dr. Setsuko Komatsu**

**Prof. Dr. Claudiu T. Supuran**

**Prof. Dr. Irmgard Tegeder**

## Message from the Editorial Board

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

## Author Benefits

**Open Access:**—free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed by the **Science Citation Index Expanded** (Web of Science), MEDLINE (PubMed), Scopus and other databases.

**Rapid Publication:** manuscripts are peer-reviewed and a first decision provided to authors approximately 13.4 days after submission; acceptance to publication is undertaken in 2.2 days (median values for papers published in this journal in the first half of 2020).

## Contact Us

*International Journal of Molecular  
Sciences*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
Fax: +41 61 302 89 18  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/ijms](http://mdpi.com/journal/ijms)  
[ijms@mdpi.com](mailto:ijms@mdpi.com)  
🐦 @IJMS\_MDPI